Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer

الملخص EN

Background.

Triweekly cisplatin-based postoperative concurrent chemoradiotherapy (CCRT) has high intolerance and toxicities in locally advanced head and neck cancer (LAHNC).

We evaluated the effect of a modified weekly cisplatin-based chemotherapy in postoperative CCRT.

Methods.

A total of 117 patients with LAHNC were enrolled between December 2007 and December 2012.

Survival, compliance/adverse events, and independent prognostic factors were analyzed.

Results.

Median follow-up time was 30.0 (3.1–73.0) months.

Most patients completed the entire course of postoperative CCRT (radiotherapy ≥ 60 Gy, 94.9%; ≥6 times weekly chemotherapy, 75.2%).

Only 17.1% patients required hospital admission.

The most common adverse effect was grade 3/4 mucositis (28.2%).

No patient died due to protocol-related adverse effects.

Multivariate analysis revealed the following independent prognostic factors: oropharyngeal cancer, extracapsular spread, and total radiation dose.

Two-year progression-free survival and overall survival rates were 70.9% and 79.5%, respectively.

Conclusion.

Modified weekly cisplatin-based chemotherapy is an acceptable regimen in postoperative CCRT for LAHNC.